Browse by category

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to research, ‘Bariatric surgery effectiveness after glp-1 agonist weight loss (abstract id: 4149)’, presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. “Patients are increasingly having surgery after GLP-1 therapy,

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to research, ‘Understanding insurance-based differential healthcare costs for GLP-1ra versus bariatric surgery (abstract id: 4339)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. “As GLP-1 use bec

A global panel of 21 obesity and cancer experts have suggested that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers. The group of experts, convened at the European Congress on Obesity (ECO2026) in Istanbul, Turkey, includi

Women who lost weight using GLP-1 medications are judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a ‘shortcut’, according to a study by Georgetown University Medical Center researchers. The study also found higher levels of stigma when the women in sample scenarios were portrayed as white rather than Black. The findings highlight how social narratives about ‘acc

More than a quarter of people with Type 2 diabetes take glucagon-like peptide-1 (GLP-1), but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a study by Stanford Medicine scientists and their collaborators. The genetic variants, carried by roughly 10% of the general population, cause a surprising and still mysterious phenomenon that researchers refer to as GLP-1 resistance, in which levels of the hormone GLP-1, which

According to researcher from Ohio State University Wexner Medical Center in Columbus, prescription for patients who were eligible for metabolic and bariatric surgery (MBS) for glucagon-like peptide-1 receptor agonist (GLP-1 RA) increased from 2018 to 2025, while MBS use decreased beginning in 2023. “To our knowledge, this is the first study to provide evidence that trends in MBS use have not yet stabilised through quarter 3 of 2025,” the researchers noted. “Stratification by

The World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease, to address the growing global health challenge of obesity that affects more than one billion people. In 2024, obesity was associated with 3.7 million deaths worldwide and without decisive action, the number of people with obesity is projected to double by 2030. In September 2025, WHO added GLP-1 ther